Investor
J.P. Morgan Life Sciences Private Capital
1$1.5bn$1.5bn0
Startups backed by J.P. Morgan Life Sciences Private Capital that were acquired: 1 exit so far, with the buyer, the price where disclosed and every source.
Photo: Maggie Bartlett, NHGRI / Wikimedia Commons, Public domainEli Lilly agrees to buy Calytrix Bio for up to $1.5 billion
J.P. Morgan's life sciences venture arm set up the Massachusetts biotech only last year, and its lead antibody for two blood cancers has not yet been tested in people.
$1.5bnn/aSeries BCorporate
Latest in J.P. Morgan Life Sciences Private Capital
All J.P. Morgan Life Sciences Private Capital exitsOpen tracker →
Eli Lilly → Calytrix Bio$1.5bn$1bn+